Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oseltamivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oseltamivir SCHEMBL13459830 | 0.95 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14775954 | 0.95 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14283136 | 0.95 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL18379765 | 0.95 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL19513553 | 0.95 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL125557 | 0.95 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL4234896 | 0.95 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL32035 | 0.95 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL9281280 | 0.94 | MEN1 (0.86) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL28487532 | 0.94 | MEN1 (0.86) | MEN1LMNACYP3A4KMT2ANEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362071-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Grünenthal GmbH (DE) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017049294-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2011097269-A9 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-2531200-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Thar Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097269-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |